BR9913472A - Novas formas hidratadas de alendronato de sódio, seus processos de fabricação e suas composições farmacêuticas - Google Patents

Novas formas hidratadas de alendronato de sódio, seus processos de fabricação e suas composições farmacêuticas

Info

Publication number
BR9913472A
BR9913472A BR9913472-1A BR9913472A BR9913472A BR 9913472 A BR9913472 A BR 9913472A BR 9913472 A BR9913472 A BR 9913472A BR 9913472 A BR9913472 A BR 9913472A
Authority
BR
Brazil
Prior art keywords
pharmaceutical compositions
new
manufacturing processes
sodium alendronate
alendronate
Prior art date
Application number
BR9913472-1A
Other languages
English (en)
Inventor
Nina Finkelstein
Ramy Lidor-Hadas
Judith Aronhime
Original Assignee
Teva Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharma filed Critical Teva Pharma
Publication of BR9913472A publication Critical patent/BR9913472A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/3804—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)] not used, see subgroups
    • C07F9/3839—Polyphosphonic acids
    • C07F9/3873—Polyphosphonic acids containing nitrogen substituent, e.g. N.....H or N-hydrocarbon group which can be substituted by halogen or nitro(so), N.....O, N.....S, N.....C(=X)- (X =O, S), N.....N, N...C(=X)...N (X =O, S)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

"NOVAS FORMAS HIDRATADAS DE ALENDRONATO DE SóDIO, SEUS PROCESSOS DE FABRICAçãO E SUAS COMPOSIçõES FARMACêUTICAS". São reveladas novas formas hidratadas de alendronato de sódio, tendo um conteúdo de água entre cerca de um e cerca de 12 por cento, e os processos para a sua fabricação. São reveladas também novas forma cristalinas de alendronato de sódio B, D, E, F, G e H, e os processos para fabrica-las. Essas novas formas de alendronato de sódio são adequadas para incorporações em composições farmacêuticas para combater a reabsorção óssea nas doenças dos ossos.
BR9913472-1A 1998-08-27 1999-08-27 Novas formas hidratadas de alendronato de sódio, seus processos de fabricação e suas composições farmacêuticas BR9913472A (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US9831398P 1998-08-27 1998-08-27
US12974399P 1999-04-16 1999-04-16
US14446199P 1999-07-19 1999-07-19
PCT/US1999/019838 WO2000012517A1 (en) 1998-08-27 1999-08-27 Novel hydrate forms of alendronate sodium, processes for manufacture thereof, and pharmaceutical compositions thereof

Publications (1)

Publication Number Publication Date
BR9913472A true BR9913472A (pt) 2002-03-05

Family

ID=27378576

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9913472-1A BR9913472A (pt) 1998-08-27 1999-08-27 Novas formas hidratadas de alendronato de sódio, seus processos de fabricação e suas composições farmacêuticas

Country Status (30)

Country Link
US (2) US6281381B1 (pt)
EP (1) EP1107974B1 (pt)
JP (2) JP2002523514A (pt)
KR (2) KR20010079701A (pt)
AT (1) ATE334993T1 (pt)
AU (1) AU5698899A (pt)
BG (1) BG65329B1 (pt)
BR (1) BR9913472A (pt)
CA (1) CA2341459A1 (pt)
CZ (1) CZ2001629A3 (pt)
DE (1) DE69932620T2 (pt)
DK (1) DK1107974T3 (pt)
EA (1) EA002739B1 (pt)
EE (1) EE04552B1 (pt)
ES (1) ES2270613T3 (pt)
HR (1) HRP20010129A2 (pt)
HU (1) HUP0203078A3 (pt)
IL (1) IL141423A (pt)
IS (1) IS5864A (pt)
LT (1) LT4888B (pt)
LV (1) LV12720B (pt)
NO (1) NO20010957L (pt)
NZ (1) NZ510682A (pt)
PL (1) PL346347A1 (pt)
PT (1) PT1107974E (pt)
RO (1) RO122854B1 (pt)
SI (1) SI20581B (pt)
SK (1) SK2482001A3 (pt)
WO (1) WO2000012517A1 (pt)
YU (1) YU14701A (pt)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE455121T1 (de) * 2001-07-16 2010-01-15 Univ Paris 13 Herstellungsverfahren von derivate von bisphosphonaten
GB2383042A (en) * 2001-10-18 2003-06-18 Cipla Ltd Amorphous alendronate sodium
NZ552513A (en) * 2001-12-24 2008-08-29 Teva Pharma Dosage form with a core tablet of active ingredient sheathed in a compressed annular body of powder or granular material, and process and tooling for producing it
US20040052843A1 (en) * 2001-12-24 2004-03-18 Lerner E. Itzhak Controlled release dosage forms
ITMI20020146A1 (it) * 2002-01-29 2003-07-29 Lyogen Ltd Alendronato monosodico amorfo e processo per la sua preparazione
CA2480814A1 (en) * 2002-04-05 2003-10-23 Merck & Co., Inc. Method for inhibiting bone resorption with an alendronate and vitamin d formulation
US20080249068A1 (en) * 2002-09-05 2008-10-09 Deluca Hector F Method of Extending the Dose Range of Vitamin D Compounds
WO2005035542A1 (en) * 2003-10-14 2005-04-21 Pliva-Istrazivanje I Razvoj D.O.O. Solid-state form of alendronate sodium and preparation thereof
US20050181043A1 (en) * 2004-02-12 2005-08-18 Indranil Nandi Alendronate salt tablet compositions
US20050261250A1 (en) * 2004-05-19 2005-11-24 Merck & Co., Inc., Compositions and methods for inhibiting bone resorption
SI1753395T1 (sl) 2004-05-24 2011-01-31 Warner Chilcott Co Llc Enterične trdne formulacije oralnih odmerkov bifosfonata, ki vsebuje kelirno sredstvo
CZ296937B6 (cs) * 2004-09-02 2006-07-12 Zentiva, A. S Trisodná sul kyseliny 4-amino-1-hydroxybutyliden-1,1-bisfosfonové
CN101044188B (zh) * 2004-10-29 2010-08-04 桑多斯股份公司 制备格拉太咪尔的方法
US20060134190A1 (en) * 2004-12-16 2006-06-22 Banner Pharmacaps Inc. Formulations of bisphosphonate drugs with improved bioavailability
CZ297262B6 (cs) * 2004-12-28 2006-10-11 Zentiva, A. S. Trisodná sul kyseliny 4-amino-1-hydroxybutyliden-1,1-bisfosfonové
US8003820B2 (en) * 2005-10-20 2011-08-23 Dr. Reddy's Laboratories Limited Process for preparing bisphosphonic acids
AR058168A1 (es) * 2005-11-07 2008-01-23 Merck & Co Inc Sintesis del alendronato de sodio trihidratado
BRPI0717394A2 (pt) * 2006-10-27 2013-10-15 Signal Pharm Llc Forma cristalina, composição farmacêutica, forma de dosagem unitária única, método para tratar ou prevenir uma doença ou condição, e, processo para preparar um composto
ES2392890T3 (es) * 2006-11-22 2012-12-14 Eisai R&D Management Co., Ltd. Sal sódica de un compuesto disacarídico, procedimiento para la producción de la misma y uso de la misma
US20090076144A1 (en) * 2007-09-17 2009-03-19 Protia, Llc Deuterium-enriched bazedoxifene
US20090118238A1 (en) * 2007-09-17 2009-05-07 Protia, Llc Deuterium-enriched alendronate
US20090170815A1 (en) * 2007-12-28 2009-07-02 Roxane Laboratories Incorporated. Alendronate oral liquid formulations
WO2011054182A1 (zh) * 2009-11-03 2011-05-12 Liu Li 丹参酮ⅱa磺酸钠水合物及其制备方法和用途
MX2021001169A (es) 2013-11-15 2023-02-10 Akebia Therapeutics Inc Formas sólidas de ácido {[5-(3-clorofenil)-3-hidroxipiridin-2-carb onil]amino}acético, composiciones, y usos de las mismas.

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3016289A1 (de) 1980-04-28 1981-10-29 Henkel KGaA, 4000 Düsseldorf Verfahren zur herstellung von omega -amino-1-hydroxyalkyliden-1,1-bis-phosphonsaeuren
IT1201087B (it) 1982-04-15 1989-01-27 Gentili Ist Spa Bifosfonati farmacologicamente attivi,procedimento per la loro preparazione e relative composizioni farmaceutiche
US4639338A (en) * 1984-08-06 1987-01-27 Ciba-Geigy Corporation Preparation of crystalline disodium 3-amino-1-hydroxypropane-1,1-diphosphonate pentahydrate
DE3434667A1 (de) * 1984-09-21 1986-04-03 Henkel KGaA, 4000 Düsseldorf 4-dimethylamino-1-hydroxybutan-1,1-diphosphonsaeure, deren wasserloesliche salze, verfahren zu ihrer herstellung sowie ihre verwendung
IT1196315B (it) * 1984-10-29 1988-11-16 Gentili Ist Spa Procedimento per la preparazione di acidi difosfonici
US4711800A (en) * 1985-06-06 1987-12-08 Divincenzo Maureen Needlecraft with metallic substrate
US4922007A (en) 1989-06-09 1990-05-01 Merck & Co., Inc. Process for preparing 4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid or salts thereof
US5019651A (en) * 1990-06-20 1991-05-28 Merck & Co., Inc. Process for preparing 4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid (ABP) or salts thereof
US5159108A (en) * 1990-09-18 1992-10-27 Merck & Co., Inc. Process for preparing an antihypercalcemic agent
US5039819A (en) * 1990-09-18 1991-08-13 Merck & Co., Inc. Diphosphonate intermediate for preparing an antihypercalcemic agent
DK0833643T3 (da) * 1995-06-06 2005-05-30 Merck & Co Inc Formuleringer af vandfrit mononatriumsalt af alendronat og deres anvendelse til behandling af knoglesygdomme
JPH11506757A (ja) * 1995-06-06 1999-06-15 メルク エンド カンパニー インコーポレーテッド 二ナトリウムアレンドロネート製剤

Also Published As

Publication number Publication date
IL141423A (en) 2005-09-25
LV12720A (lv) 2001-09-20
HUP0203078A3 (en) 2005-01-28
EE04552B1 (et) 2005-10-17
SI20581B (sl) 2008-06-30
IS5864A (is) 2001-02-26
ES2270613T3 (es) 2007-04-01
SI20581A (sl) 2001-12-31
KR20070034132A (ko) 2007-03-27
NO20010957L (no) 2001-04-26
LT4888B (lt) 2002-02-25
RO122854B1 (ro) 2010-03-30
JP2002523514A (ja) 2002-07-30
NZ510682A (en) 2003-09-26
KR20010079701A (ko) 2001-08-22
CZ2001629A3 (cs) 2001-08-15
JP2009143955A (ja) 2009-07-02
BG105292A (en) 2001-12-29
EP1107974A1 (en) 2001-06-20
DK1107974T3 (da) 2006-10-30
EA200100184A1 (ru) 2001-10-22
US6696601B2 (en) 2004-02-24
LV12720B (en) 2002-02-20
EP1107974A4 (en) 2001-09-26
ATE334993T1 (de) 2006-08-15
PT1107974E (pt) 2006-10-31
HUP0203078A2 (hu) 2003-01-28
BG65329B1 (bg) 2008-02-29
EA002739B1 (ru) 2002-08-29
WO2000012517A9 (en) 2000-07-13
US20030065214A1 (en) 2003-04-03
HRP20010129A2 (en) 2005-04-30
AU5698899A (en) 2000-03-21
WO2000012517A1 (en) 2000-03-09
EE200100126A (et) 2002-06-17
PL346347A1 (en) 2002-02-11
EP1107974B1 (en) 2006-08-02
NO20010957D0 (no) 2001-02-26
US6281381B1 (en) 2001-08-28
LT2001016A (en) 2001-10-25
DE69932620T2 (de) 2006-12-14
YU14701A (sh) 2003-01-31
CA2341459A1 (en) 2000-03-09
DE69932620D1 (de) 2006-09-14
IL141423A0 (en) 2002-03-10
SK2482001A3 (en) 2002-01-07

Similar Documents

Publication Publication Date Title
BR9913472A (pt) Novas formas hidratadas de alendronato de sódio, seus processos de fabricação e suas composições farmacêuticas
ES513235A0 (es) "procedimiento para la preparacion de nuevas formas orales de dipiridamol, en forma de granulados, pastillas o tabletas".
BR0009964A (pt) Peptìdios artificiais com atividade desuperfìcie e sua utilização na preparação de surfactante artificial
BR9906438A (pt) Composição de reforço nutricional apropriada para o tratamento de úlceras de pressão
BR9916307A (pt) Derivados quinolina
PT1117645E (pt) Derivados de propanolamina arilo substituidos metodos para o seu fabrico medicamentos contendo estes compostos e sua utilizacao
PT782449E (pt) Processo de fabrico de unidades de dosagem por granulacao humida
IT8748544A0 (it) Alfa-amminoacidi sostituiti,loro preparazione e composizioni farmaceutiche che li contengono
BR9808140A (pt) Formulação unitária
BR9911884A (pt) Preparação farmacêutica
IT8721109A0 (it) Elemento di quarzo fuso da impiegare nella fabbricazione di semiconduttori.
IT8547877A0 (it) Alfa-amminoacidi,la loro preparazione e lecoomposizioni farmaceutihe che li contengono
CO4970795A1 (es) Polisacaridos de sintesis, procedimiento para su preparacion y composiciones farmaceuticas que los contienen
TR199900548A3 (tr) Düsük kesme kuvvetli taneleme kullanilarak dozaj birimlerinin yapimi.
PT862575E (pt) Novos derivados de geranilgeranilo processo para a sua preparacao e composicoes farmaceuticas relacionadas
ATE201680T1 (de) 2,3,4,5-tetrahydro-1h-3-benzazepin säure- additions-salze
AU2195800A (en) Bis-amido polybiguanides and the use thereof to disinfect contact lenses and preserve pharmaceutical compositions
ATE125541T1 (de) Reine kristalline form von rifapentin.
BR9803949A (pt) Cristais de maltitol de formas particulares, composições cristalinas contendo os mesmos e processo para fabriacação dos mesmos
EP1702924A3 (en) Novel hydrate forms of alendronate sodium, processes for manufacture thereof, and pharmaceutical compositions thereof
NO894516D0 (no) Fremgangsmaate for fremstilling av 1-aminoalkyl-3-oksosubstituert-4-aryl-1,3,4,5-tetrahydro-2h-1,3-benzodiazepin-2-on, og deres anvendelse som medikamenter.
FR2722131B1 (fr) Procede de preparation de melanges aqueux agrileux pompables
NO901892D0 (no) Fremgangsmaate for fremstilling av (2,1-c)(1,3)-benzodiazepiner og deres anvendelse som medikamenter.
ES555075A0 (es) Procedimiento para la fabricacion de calzado en una sola pieza
BR8300822A (pt) Incorporacao de fragrancia de perfumes na fabricacao de calcados,de lona e outros

Legal Events

Date Code Title Description
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements